Cytotoxic Chemotherapy in Kaposi’s Sarcoma

  • Steven A. Armentrout
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 187)


Kaposi’s sarcoma, recognized in the Western Hemisphere as an indolent malignant cutaneous disease affecting primarily elderly males of Jewish extraction, has in recent years been the principle malignancy associated with acquired immune deficiency syndrome (AIDS). The wide-spread cutaneous lesions are frequently associated with viseral involvement, particularly in the pulmonary and gastrointestinal systems. The early cutaneous manifestations of Kaposi’s sarcoma appear to respond to the administration of interferon. This biologic has not, however, afforded permanent control in this disease. A variety of chemotherapeutic regimens have been employed in an effort to control advanced cutaneous and viseral Kaposi’s sarcoma (1–7). The use of cytotoxic chemotherapy has resulted in a substantial percentage of partial and complete responses in the malignant lesions. The duration of both complete and partial responses has, however, proved disappointingly short. Another theoretical as well as practical disadvantage of cytotoxic chemotherapy, has been a further suppression of the immune system in the patient with AIDS. Although frequently difficult to quantitate, this appears to have resulted in a further increase in systemic life threatening infections by both common and opportunistic pathogens. Recent trials of chemotherapy employing both cytotoxic chemotherapy and biologic response modifiers, although too early to evaluate, seem to produce results similar to cytotoxic chemotherapy alone.


Acquire Immune Deficiency Syndrome Cytotoxic Chemotherapy Biologic Response Modifier Mixed Response Symptomatic Anemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    B. Safai, Clinical features of Kaposi’s sarcoma/aquired immune deficiency syndrome and its management, Antibiot-Chemother. 32: 54–70 (1983).PubMedGoogle Scholar
  2. 2.
    A. C. Bayley, Aggressive Kaposi’s sarcoma in Zambia, 1983, Lancet 1: 1318–20 (1984).PubMedCrossRefGoogle Scholar
  3. 3.
    A. Poulsen, B. Hultberg, K. Thomsen, and G. L. Wantzin, Regression of Kaposi’s sarcoma in AIDS after treatment with dapsone, Lancet 1: 560 (1984).PubMedCrossRefGoogle Scholar
  4. 4.
    K. H. Antman, L. Nadler, E. J. Mark, D. L. Montella, P. Kirkpatrick, and J. Halpern, Primary Kaposi’s sarcoma of the lung in an immunocompetent 32-year-old heterosexual white man, Cancer 54: 1696–8 (1984).PubMedCrossRefGoogle Scholar
  5. 5.
    M. Markowitz, C. Metroka, and A. Moore, VP 16–213 (Etoposide) and bleomycin in the treatment of Kaposi’s sarcoma, Proc Annu Meet Am Soc Clin Oncol 3: 58 (1984).Google Scholar
  6. 6.
    K. K. Ketiku and F. A. Durosinmi-Etti, The treatment of Kaposi’s sarcoma by combination chemiotherapy in Nigeria, Clin Radiol 35: 155–8 (1984).PubMedCrossRefGoogle Scholar
  7. 7.
    B. Lewis, D. Abrams, J. Ziegler, M. Conant, G. Gee, I. Silverberg, and P. Volberding, Single agent or combination chemotherapy of Kaposi’s sarcoma (KS) in aquired immune deficiency syndrome (AIDS), Proc Am Soc Clin Oncol 2:C–232 (1983).Google Scholar

Copyright information

© Plenum Press, New York 1985

Authors and Affiliations

  • Steven A. Armentrout
    • 1
  1. 1.University of California, IrvineIrvineUSA

Personalised recommendations